术后辅助放疗在局限期小细胞肺癌中的应用:一项系统综述与荟萃分析
该系统综述与荟萃分析纳入11项回顾性研究共7694例局限期小细胞肺癌患者,比较术后辅助放疗与未放疗的预后。结果显示,整体人群接受术后辅助放疗者总生存优于未接受者(HR 0.79,95%CI 0.71-0.87,P<0.0001);pN0期患者接受术后辅助放疗对总生存不利(HR 1.22,95%CI 1.04-1.43,P=0.01);pN2期患者接受术后辅助放疗总生存显著改善(HR 0.59,95%CI 0.50-0.70,P<0.0001)。
要点
- 整体局限期小细胞肺癌人群接受术后辅助放疗者总生存优于未接受者(HR 0.79,95%CI 0.71-0.87,P<0.0001)。
- pN0期患者接受术后辅助放疗对总生存不利(HR 1.22,95%CI 1.04-1.43,P=0.01)。
- pN2期患者接受术后辅助放疗总生存显著改善(HR 0.59,95%CI 0.50-0.70,P<0.0001)。
核心结论
- 就总生存而言,pN0或pN1期局限期小细胞肺癌患者不宜行术后辅助放疗,而pN2期患者强烈推荐行术后辅助放疗。
- 作者认为需进一步研究以证实上述发现。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library三个数据库。
- 纳入11项回顾性研究,共7694例符合条件的局限期小细胞肺癌患者。
- 采用随机效应模型和固定效应模型合并结果,比较接受与未接受术后辅助放疗患者的预后。
- 主要结局为总生存,次要结局为无病生存。
主要发现
- 整体局限期小细胞肺癌人群中,接受术后辅助放疗者总生存优于未接受者(HR 0.79,95%CI 0.71-0.87,P<0.0001)。
- pN0期局限期小细胞肺癌患者中,术后辅助放疗对总生存有不利影响(HR 1.22,95%CI 1.04-1.43,P=0.01)。
- pN1期局限期小细胞肺癌患者中,加用术后辅助放疗相比未加用未提供显著的总生存优势(HR 0.82,95%CI 0.60-1.12,P=0.21)。
- pN2期局限期小细胞肺癌患者中,接受术后辅助放疗者相比未接受者总生存显著改善(HR 0.59,95%CI 0.50-0.70,P<0.0001)。
- 局限期小细胞肺癌患者无病生存方面,接受与未接受术后辅助放疗的保护效应差异较不明显(HR 0.76,95%CI 0.58-1.00,P=0.053)。
关键数值与推荐
- pN0期局限期小细胞肺癌:术后辅助放疗对总生存不利(HR 1.22,95%CI 1.04-1.43,P=0.01),作者结论为不宜行术后辅助放疗。
- pN1期局限期小细胞肺癌:术后辅助放疗相比未放疗未提供显著总生存优势(HR 0.82,95%CI 0.60-1.12,P=0.21),作者结论为不宜行术后辅助放疗。
- pN2期局限期小细胞肺癌:术后辅助放疗相比未放疗总生存显著改善(HR 0.59,95%CI 0.50-0.70,P<0.0001),作者结论为强烈推荐行术后辅助放疗。
临床怎么用
- 作者结论认为,就总生存而言,pN0或pN1期局限期小细胞肺癌患者不宜行术后辅助放疗。
- 作者结论认为,就总生存而言,pN2期局限期小细胞肺癌患者强烈推荐行术后辅助放疗。
- 作者认为需进一步研究以证实上述发现。
局限性
- 纳入的11项研究均为回顾性研究。
- 作者认为需进一步研究以证实上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: One of the most important treatments for small cell lung cancer (SCLC) is radiation therapy. Currently, the criteria for administering postoperative adjuvant radiotherapy (PORT) in SCLC remain uncertain. Therefore, we conducted a meta-analysis to investigate the influence of PORT on the prognosis of limited-stage SCLC (LS-SCLC). METHODS: We conducted a comprehensive search across three databases, PubMed, Embase, and the Cochrane Library. Data analysis involved utilizing both random-effects and fixed-effects models for pooling the results. A comparative analysis was performed to assess the prognostic outcomes of patients with LS-SCLC who did and did not undergo PORT. The primary outcome assessed was overall survival (OS), while the secondary outcome was disease-free survival (DFS). RESULTS: This analysis included 11 retrospective studies comprising 7694 eligible participants. Among the entire population of LS-SCLC patients, the OS was superior in those receiving PORT than in those not receiving it (hazard ratio [HR]: 0.79, 95 % confidence interval [CI]: 0.71-0.87; P < 0.0001). In pN0 stage LS-SCLC patients, PORT was associated with a detrimental effect on OS (HR: 1.22, 95 % CI: 1.04-1.43; P = 0.01). In pN1 stage LS-SCLC patients, additionally administering PORT did not provide a significant OS advantage as compared to not administering it (HR: 0.82, 95 % CI: 0.60-1.12; P = 0.21). In pN2 stage LS-SCLC patients, those receiving PORT demonstrated a significant improvement in OS (HR: 0.59; 95 % CI: 0.50-0.70; P < 0.0001) as compared to those not receiving it. Regarding DFS in LS-SCLC patients, the difference in the protective effect with and without the administration of PORT was less pronounced (HR: 0.76, 95 % CI: 0.58-1.00; P = 0.053). CONCLUSIONS: With respect to OS, PORT is not advisable in patients with pN0 or pN1 stage LS-SCLC but is highly recommended in pN2 stage LS-SCLC. Further research is warranted to confirm these findings.
引用
- Zhang C, Zhao G, Wu H, et al. Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis. Radiother Oncol. 2024. PMID: 38309584. doi:10.1016/j.radonc.2024.110123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。